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3To the Editor:
Choi et al provided a comprehensive review of programmed cell 
death 1 protein (PD-1) and programmed death-ligand 1 (PD-L1) 
inhibitors in the treatment of nonmelanoma skin cancer.1  However, 
they incorrectly commented that the new primary cutaneous 
superficial basal cell carcinomas (BCCs) that paradoxically developed 
in our patient with metastatic BCC also responded to nivolumab.2-4  We 
want to emphasize this important observation, since it provides 
additional insight into the mechanism of therapeutic benefit and 
limitations when immunotherapy is considered for patients with 
metastatic BCC, and to share the features of additional patients with 
advanced or metastatic BCC who were treated with checkpoint 
inhibitors.4,5
The first patient, a 58-year-old man, developed new primary 
cutaneous BCCs nine months after initiating nivolumab and achieving 
near complete remission of his widely metastatic BCC.  His metastatic 
tumor had been refractory to treatment with chemotherapy (cisplatin 
and paclitaxel) and Hedgehog pathway inhibitors (vismodegib and 
sonidegib; the latter was combined with buparlisib, a pan-class I PIK3 
inhibitor).  Next generation sequencing (NGS) of his liver metastasis 
not only demonstrated multiple genomic alterations (including PD-L1 
amplification), but also a tumor mutational burden (TMB) of 103 
mutations per megabase (m/mb); >20 m/mb is considered to be a high
3
4TMB and associated with better responses to immunotherapy.  In 
contrast, the new primary cutaneous BCCs had fewer genomic 
alterations, did not exhibit PD-L1 amplification, and had a lower TMB of
45 m/mb.2-4,6
The second patient, a 62-year-old man, presented with an 
advanced BCC on his upper back (Figure 1a).  NGS of his tumor 
demonstrated 11 significant genomic variants and a high TMB (53 
m/mb).  He was treated with vismodegib and nivolumab. He achieved 
complete remission after five months of treatment. Vismodegib was 
stopped after 8.5 months.  He continues to remain in remission more 
than 12 months after stopping therapy (Figure 1b).4,5
The third patient, a 53-year-old woman, had metastatic BCC.  
NGS of her cutaneous and metastatic tumor demonstrated six and 12 
genomic alterations, respectively; both tumors had a high TMB (90 m/
mb).  She achieved partial remissions with vismodegib and 
subsequently nivolumab;  however, her progression free survival was 
only 4.5 months and 3.8 months, respectively.4
The fourth patient, a 50-year-old woman, had metastatic BCC; 
NGS demonstrated ten genomic alterations and a TMB of 102 m/mb.  
Vismodegib resulted in a partial remission lasting 11.1 months; 
progressive disease occurred 2.5 months after starting 
pembrolizumab.4
4
5In summary, we propose that checkpoint inhibitors may be more 
successful in patients with ‘late’ metastatic disease in which the tumor 
has more genomic aberrations and high TMB.  In contrast, treatment 
with targeted therapies such as vismodegib (or excision for localized 
disease) may be better for patients with genomically less complex 
BCCs.  In our patient, the paradoxical development of new superficial 
cutaneous BCC—in the setting of concurrently receiving 
immunotherapy and achieving near complete remission of his 
metastatic BCC—occurred since the checkpoint inhibitor was not able 
to prevent his ‘early’ neoplastic disease that was characterized by 
fewer molecular alterations and a lower TMB.
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Figure 1 (a and b).  An advanced BCC (10 x 8 x 2.5 cm) without 
metastatic disease on the upper back of a 62-year-old man (a); the 
erythema on his back surrounding the tumor was caused by allergic 
contact dermatitis to band aid adhesive.  He was treated concurrently 
with four total intravenous doses of nivolumab (240 mg for three doses
and 120 mg for the final dose) and oral vismodegib (150 mg daily); the
nivolumab was discontinued because of steroid-responsive grade three
skin rash and recurrent transaminitis.  After five months of treatment, 
he achieved a complete and sustained remission; multiple skin 
biopsies showed no evidence of disease.  The vismodegib was stopped 
after 8.5 months secondary to loss of appetite in the setting of 
complete remission.  There is no recurrence at follow up nine months 
after stopping treatment (b).
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